(Synonyms: )

CS476 is a potent hypoglycaemic agent. In Vivo: In normal fasting dogs, rabbits, rats and mice the maximal hypoglycaemia produced by intravenous administration of CS476 is comparable on a weight basis to that produced by Glibenclamide. Randomized Latin square experiments in dogs show that 0.03 mg/kg orally of CS476 and of Glibenclamide cause the same maximal decrease of blood glucose and that CS476 has the shorter duration of action. CS476 has no hypoglycaemic effect in totally pancreatectomized dogs nor in streptozotocin diabetic dogs and rats. The insulin releasing activity is studied in dogs after intravenous and oral administration of equipotent doses of CS476, Tolbutamide and Glibenclamide^[1].

471.57

C₂₄H₂₉N₃O₅S

41177-35-9

O=C(C1=C(OCC2)C2=CC=C1)NCCC3=CC=C(S(=O)(NC(NC4CCCCC4)=O)=O)C=C3

Room temperature in continental US; may vary elsewhere.

• [1]. Jorgensen KD. The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect. Acta Pharmacol Toxicol (Copenh).  [Content Brief]